FILING ANALYSIS · THURSDAY, NOVEMBER 19

PharmaCyte Biotech, Inc. PMCB — 8-K: Entry into a Material Definitive Agreement

neutral

PharmaCyte Biotech, Inc. exchanged 851,304 Series G Long-Term Warrants for 4,982,272 shares of Q/C Technologies, Inc. common stock, and also consented to extend the maturity date of Q/C's Series H Convertible Preferred Stock, which it holds a majority of, by six months to September 2, 2027, with no additional consideration paid, in a related-party deal with its CEO also serving as Q/C's CEO.

The filing

8-K - PharmaCyte Biotech, Inc. (0001157075) (Filer)

Read the filing on SEC EDGAR →

How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.

Get filings like this every market day

The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.

Subscribe free →
All analyses · Earnings today · Latest brief · Track record
© 2026 Dutchcode B.V. · Built by
Blinkof.ai verified — grade A+